Adaptive Clinical Trials Should Still Be Designed “Conservatively,” Integra Consultant Says
This article was originally published in The Pink Sheet Daily
Assuming a study will need to be large could lead to cost-savings if stopped early, while starting with a small design could result in problems if expansion is needed.
You may also be interested in...
Overseas clinical trials could save companies money, but consultants on a regulatory panel at the Biotechnology Industry Organization's Mid-America VentureForum in Cleveland suggested such studies might not be worth the oversight costs
The agency will issue a total of five guidance documents regarding adaptive clinical trials, the first of which will examine using multiple endpoints in the same trial.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.